Mass Spectrometry Proteomic Profiles of Human Tauopathy Brains

Mass spectrometry data from postmortem brain homogenates of 16 subjects, including Alzheimer's disease, corticobasal degeneration, progressive supranuclear palsy, and control cases. The dataset was created by Alfi Raudatil Jannah and last updated in May 2026. It includes 859 differentially expressed proteins and validation results from western blotting and immunohistochemistry.

Use Cases

• Identifying proteomic signatures for primary and secondary tauopathies based on mass spectrometry data.
• Analyzing protein-protein interaction networks enriched for mitochondrial pathways like oxidative phosphorylation.
• Validating mass spectrometry findings using complementary techniques like western blotting and immunohistochemistry mentioned in the description.
• Investigating cell-type-specific transcriptomic alterations associated with tauopathies based on single-nucleus RNA sequencing.

Strengths

• Includes validation data from western blotting, immunohistochemistry, and single-nucleus RNA sequencing.
• Identified 859 differentially expressed proteins with a false discovery rate (FDR) < 0.05.
• Data is shared under a permissive CC-BY-4.0 license.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• The study's exploratory nature suggests findings are hypothesis-generating and require further investigation.
• The dataset is small at 4.2 MB, which may limit the scope of analysis.

Provenance

Source

figshare

Collection Method

Mass spectrometry analysis of total homogenates from postmortem human brain tissue.

Freshness

Last updated 2026-05-22 06:11:00